Hypertrophic obstructive cardiomyopathy (HOCM), the cause of which is unknown, is a heart disease characterized by obstruction of the left ventricular outflow tract and an increase in interventricular septum thickness. Octreotide, a synthetic analogue of somatostatin, was administered subcutaneously to 15 patients for 6 months in order to determine its efficacy in HOCM. Echocardiographic examination was performed in each patient before we had initiated treatment and after treatment. Interventricular septum thickness, interventricular septum thickness/left ventricular posterior wall thickness, and subaortic gradient decreased significantly at the end of treatment. The ratio of the mitral valve E to A waves increased significantly. We observed that octreotide treatment caused a significant decrease in interventricular septum thickness and subaortic pressure gradient. Before and after therapy left ventricular enddiastolic diameter, left ventricular endsystolic diameter, ejection fraction and fractional shortening were not changed. No adverse effect was observed during the therapy. According to our results, octreotide has some beneficial effects on HOCM and it seems to be a new therapeutic approach for HOCM. (Jpn Heart J 1998; 39: 173-181) 
include (a) abnormally thickened small intramural arteries causing ischemia and resulting in compensatory hypertrophy and fibrosis2); (b) subendocardial ischemia caused by microcirculatory abnormalities which decreases the energy stores and results in the inhibition of the disengagement of the contractile elements and increase in diastolic wall thickness3); (c) hypersensitivity to the effects of insulin like growth factor I (IGF-I) or increase in the density of IGF-I receptors, and (d) sympathetic overstimulation.
Current medical approaches do not attack the underlying pathology but only relieve the symptoms.1,4-7) Surgical therapy has high mortality and high recurrence rates.8,9) Because of this new therapeutic strategies are being investigated.
Octreotide is a synthetic analogue of somatostatin. It has a much longer half-life and is 45 times more effective than somatostatin.9,10) A variety of studies have shown that it might be effective on the suggested mechanisms of HOCM mentioned above and it can decrease cardiac mass in acromegaly.11,12) However, no study has evaluated the effects of octreotide on HOCM. In this study, our goal was to evaluate the effect and safety of octreotide in HOCM. 
MATERIALS AND METHODS

Patients
DISCUSSION
In obstructive hypertrophic cardiomyopathy, the thickening is localized to the basal septum. This thickening is most prominent at the level of the mitral valve and results in a subaortic pressure gradient. There is controversy about the main pathology leading to the pressure gradient. Some authors have suggested that interventricular septum thickening is the most important pathology while others suggest that SAM of the mitral anterior leaflet is the main problem.14-16) We believe that the most important pathology is the thickening of the interventricular septum because SAM is dependent on this pathology as well. The left ventricular outflow tract is narrowed by interventricular septum thickening. As a result, early systolic ejection is rapid (and unobstructed) and the ejection path passes closer to the mitral leaflets than is normal. Systolic anterior motion of the anterior mitral leaflet results from the Venturi effect on this leaflet caused by the rapid early ejection.17,18) The obstruction to outflow results from subsequent mitral leaflet-septal contact. This view is supported by the fact that SAM decreases after myotomy or myectomy. For this reason, we believe that any intervention which does not decrease the interventricular septum thickening can not be an efficient therapeutic approach. This evidence suggests that current therapeutic approaches are not sufficiently effective and new therapeutic modalities which reduce the interventricular septum thickness should be investigated.
Octreotide has been tried in the treatment of acromegalic cardiomyopathy. The study of Pereira, et al. 19 ) has shown that octreotide used for 6 months has decreased the cardiac mass significantly and relieved diastolic dysfunction. Tokgozoglu, et al.20) reported that the cardiac mass decreased from 304g to 175 g after 6-month octreotide treatment. In another recent study, Gunal, et al. 21 ) reported a case of HOCM in which octreotide treatment resulted in a decrease in left ventricular mass. This suggestion was the main reason for us to investigate the effects of octreotide on HOCM.
None of the patients received any therapeutics other than octreotide from 7 days before to the end of treatment. No adverse effects were observed during the treatment which required the withdrawal of octreotide therapy. Local disturbances around the injection site were observed in three patients. It was then realised that these patients were administering the preparation soon after getting it from the refrigerator. After instructing them to administer the preparation after first warming it to body temperature, those disturbances disappeared. Two patients reported fecal softening, but they were not severe enough to require the withdrawal of treatment or any supportive therapy.
At the end of therapy, subaortic pressure gradient, thickness of the interventricular septum and the ratio of interventricular septum/left ventricular posterior wall decreased and the E/A ratio increased significantly. There were no significant variations in heart rate, systolic and diastolic arterial blood pressure and left ventricular posterior wall thickness (Table  IV) . 
